BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 9241127)

  • 1. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis.
    Adachi JD; Bensen WG; Brown J; Hanley D; Hodsman A; Josse R; Kendler DL; Lentle B; Olszynski W; Ste-Marie LG; Tenenhouse A; Chines AA
    N Engl J Med; 1997 Aug; 337(6):382-7. PubMed ID: 9241127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pooled data analysis on the use of intermittent cyclical etidronate therapy for the prevention and treatment of corticosteroid induced bone loss.
    Adachi JD; Roux C; Pitt PI; Cooper C; Moniz C; Dequeker J; Ioannidis G; Cawley MI; Jenkins EA; Walker-Bone KE; Pack S; Stephenson GF; Laan RF; Brown J; Geusens P
    J Rheumatol; 2000 Oct; 27(10):2424-31. PubMed ID: 11036840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S; Ohosone Y; Suwa A; Yasuoka H; Nojima T; Fujii T; Kuwana M; Nakamura K; Mimori T; Hirakata M
    J Rheumatol; 2003 Dec; 30(12):2673-9. PubMed ID: 14719212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB; Harris ST; Genant HK; Wasnich RD; Miller PD; Jackson RD; Licata AA; Ross P; Woodson GC; Yanover MJ
    N Engl J Med; 1990 Jul; 323(2):73-9. PubMed ID: 2113611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group.
    Saag KG; Emkey R; Schnitzer TJ; Brown JP; Hawkins F; Goemaere S; Thamsborg G; Liberman UA; Delmas PD; Malice MP; Czachur M; Daifotis AG
    N Engl J Med; 1998 Jul; 339(5):292-9. PubMed ID: 9682041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longterm effect of intermittent cyclical etidronate therapy on corticosteroid-induced osteoporosis in Japanese patients with connective tissue disease: 7-year followup.
    Sato S; Takada T; Katsuki Y; Kimura N; Kaneko Y; Suwa A; Hirakata M; Kuwana M
    J Rheumatol; 2008 Jan; 35(1):142-6. PubMed ID: 18050368
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 36 month intermittent cyclical etidronate treatment in patients with established corticosteroid induced osteoporosis.
    Sebaldt RJ; Ioannidis G; Adachi JD; Bensen WG; Bianchi F; Cividino A; Gordon M; Kaminska E; Scocchia T; Petrie A; Stephenson GF; Goldsmith CH
    J Rheumatol; 1999 Jul; 26(7):1545-9. PubMed ID: 10405943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of effect of cyclical etidronate in the prevention of corticosteroid-induced bone loss. Ciblos Study Group.
    Roux C; Oriente P; Laan R; Hughes RA; Ittner J; Goemaere S; Di Munno O; Pouillès JM; Horlait S; Cortet B
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1128-33. PubMed ID: 9543129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study.
    Boonen S; Orwoll ES; Wenderoth D; Stoner KJ; Eusebio R; Delmas PD
    J Bone Miner Res; 2009 Apr; 24(4):719-25. PubMed ID: 19049326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss.
    Adachi J; Cranney A; Goldsmith CH; Bensen WG; Bianchi F; Cividino A; Craig GL; Kaminska E; Sebaldt RJ; Papaioannou A
    J Rheumatol; 1994 Oct; 21(10):1922-6. PubMed ID: 7837160
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M; Kushida K; Kishimoto H; Shiraki M; Taketani Y; Minaguchi H; Inoue T; Morita R; Morii H; Yamamoto K; Ohashi Y; Orimo H;
    Osteoporos Int; 2002 Dec; 13(12):971-9. PubMed ID: 12459940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
    Storm T; Kollerup G; Thamsborg G; Genant HK; Sørensen OH
    J Rheumatol; 1996 Sep; 23(9):1560-4. PubMed ID: 8877926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T; Thamsborg G; Steiniche T; Genant HK; Sørensen OH
    N Engl J Med; 1990 May; 322(18):1265-71. PubMed ID: 2109197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial. European Corticosteroid-Induced Osteoporosis Treatment Study.
    Reid DM; Hughes RA; Laan RF; Sacco-Gibson NA; Wenderoth DH; Adami S; Eusebio RA; Devogelaer JP
    J Bone Miner Res; 2000 Jun; 15(6):1006-13. PubMed ID: 10841169
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.
    Sambrook P; Birmingham J; Kelly P; Kempler S; Nguyen T; Pocock N; Eisman J
    N Engl J Med; 1993 Jun; 328(24):1747-52. PubMed ID: 7684512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclical etidronate reverses bone loss of the spine and proximal femur in patients with established corticosteroid-induced osteoporosis.
    Struys A; Snelder AA; Mulder H
    Am J Med; 1995 Sep; 99(3):235-42. PubMed ID: 7653482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A cost effectiveness analysis of calcium and vitamin D supplementation, etidronate, and alendronate in the prevention of vertebral fractures in women treated with glucocorticoids.
    Buckley LM; Hillner BE
    J Rheumatol; 2003 Jan; 30(1):132-8. PubMed ID: 12508402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis.
    Storm T; Steiniche T; Thamsborg G; Melsen F
    J Bone Miner Res; 1993 Feb; 8(2):199-208. PubMed ID: 8442438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study.
    Geusens P; Dequeker J; Vanhoof J; Stalmans R; Boonen S; Joly J; Nijs J; Raus J
    Ann Rheum Dis; 1998 Dec; 57(12):724-7. PubMed ID: 10070271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.